Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …

The incretin hormone, glucagon-like peptide-1 (GLP-1), is now being used in the clinic to
enhance insulin secretion and reduce body weight in patients with type 2 diabetes. Although …

Glucagon-like peptide–1 (GLP-1) is an incretin hormone that lowers blood glucose after
meals in type 2 diabetes mellitus. The therapeutic potential of GLP-1 in diabetes is limited by …

Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk
factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) …

Aims Glucagon-like peptide 1 (GLP-1) is a gut incretin hormone inducing post-prandial
insulin secretion. Glucagon-like peptide 1 levels were recently found to be increased in …

CONTEXT: To examine whether widespread tissue expression of the glucagon-like peptide
(GLP)-1 receptor supports the possibility of differential effects of GLP-1-based therapeutics …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

Endothelial dysfunction is a major characteristic of the atherosclerotic process and can be
used to predict the outcome of cardiovascular disease in humans. Together with obesity and …

Background The dipeptidyl peptidase-4 (DPP-4) inhibitors Sitagliptin and Vildagliptin lower
blood glucose by augmenting endogenous levels of glucagon-like peptide-1 (GLP-1), an …

Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, with as
many as 415 million patients worldwide. T2DM is characterized by elevated blood glucose …